Back to search results

Rocklatan for Pressure Reduction After Glaucoma Surgery

This study is looking at whether adding Rocklatan (a combination eye drop of netarsudil and latanoprost) can further lower eye pressure in people with primary open-angle glaucoma (a common eye condition that damages the optic nerve) who have already had cataract surgery and a Hydrus microstent (a tiny device to help drain fluid from the eye) implanted. You might be able to join if you are 40 or older, have mild to moderate open-angle glaucoma, and had your Hydrus microstent implanted between 3 months and 2 years ago. The main goal is to see how much Rocklatan changes your eye pressure compared to a placebo (Systane artificial tears) after about one month. The study is currently recruiting participants.

Study design
This study will involve 68 participants and is designed as a randomized, double-blind study, meaning you would be randomly assigned to receive either Rocklatan or Systane, and neither you nor your doctor would know which one you are receiving.
What's involved
You would have your eye pressure measured at the start of the study and again about one month after you begin using the study eye drops.
Compensation
Not stated in the trial record.
Follow-up
Your eye pressure will be measured again about 28 to 35 days after you start using the study eye drops.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07048886

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

Not Yet Recruiting
PHASE4Ages 40+InterventionalTreatment
Center for Sight Las Vegas
~68 participants
Updated 2025-07-03 on ClinicalTrials.gov
What's tested:Rocklatan (netarsudil 0.02% and latanoprost 0.005%)Systane

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean diurnal intraocular pressure change from baseline
Measured over After 28 days up to 35 days post initiation of Rocklatan vs placebo comparator

Conditions

Primary Open Angle Glaucoma

Explore related trials

Primary Open Angle Glaucoma

Where it's being run

1 sites across 1 states
Nevada1

Study leadership

  • Medical Director, Medical Doctor · PRINCIPAL_INVESTIGATOR · Center For Sight

Who to contact

Clinical Research Manager
[email protected]
702-724-2005
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 40 years and older
Subjects who have mild to moderate Open Angle Glaucoma (OAG)
Subjects who have undergone uncomplicated cataract surgery and Hydrus microstent implantation \> 3 months prior to screening and within the last 2 years
Post-Hydrus subjects on 0-2 ocular hypotensive medication classes who can safely washout (if on ocular hypotensive medications)
Unmedicated or washed out IOP range between 16-26 mmHg

Exclusion

History of intraocular surgery except for uneventful refractive surgery or uncomplicated cataract surgery and hydrus microstent implantation
Prior Selective Laser Trabeculoplasty (SLT) within 18 months of surgery
Secondary glaucoma excluding pseudoexfoliation and pigmentary dispersion syndrome
Severe Open Angle Glaucoma
Narrow angles, other angle abnormalities or angle closure glaucoma
Allergy or intolerance to Rocklatan
History of corneal edema, or corneal disease or dystrophy
Current or history of intra-ocular infection or inflammation
History of retinal diseases that could affect diagnostic testing
Anticipated use of intra-ocular or topical steroids not associated with the study protocol
Pregnant, breastfeeding or planning to become pregnant during the study
Any condition in the opinion in the investigator that would potentially confound the results of the study

What this trial measures

  • Mean diurnal intraocular pressure change from baselineAfter 28 days up to 35 days post initiation of Rocklatan vs placebo comparator

    After Hydrus prior to study initiation drop